Publications

Featured Publications

Expert consensus on the management of pharmacodynamic breakthrough-hemolysis in treated paroxysmal nocturnal hemoglobinuria

David Dingli, Carlos De Castro III, Jamie Koprivnikar, Austin Kulasekararaj, Jaroslaw Maciejewski, Brian Mulherin, Jens Panse, Vinod Pullarkat, Alexander Röth, Jamile Shammo, Louis Terriou, Ilene Weitz, Irina Yermilov, Sarah Gibbs, Michael Broder, David Beenhouwer & David Kuter

Hematology

2024

Download

Understanding the Burden of Illness in People with Nonrelapsing Secondary Progressive Multiple Sclerosis in the United States: A Matched-cohort Study

Greene N, Das AK, Hemin I, Chang E, Tarbox MH, Higuchi K

AAN 2024 Annual Meeting

2024

Download

Value of next generation sequencing (NGS) testing in advanced cancer patients

Jesse D. Ortendahl, Gebra Cuyun Carter, Snehal G. Thakkar, Katalin Bognar, David W. Hall & Yara Abdou

Journal of Medical Economics

2024

Download

2016

Can Patient and Provider Education Increase Insulin Initiation?

Download Publication

2016

Reliability and Consistency of Three Value Frameworks for Oncology Therapeutics

Download Publication

2016

Graphical Analysis of Treatment Patterns among Patients with Pancreatic Neuroendocrine Tumors Newly Treated with Cytotoxic Chemotherapy or Targeted Therapy

Download Publication

2016

Comparison of Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis and Taking Subcutaneously Administered Disease Modifying Therapies: Interferon Beta 1b Versus 1a

Download Publication

2016

Health Economic Evaluation of Orally Versus Subcutaneously Administered Disease Modifying Therapies for Patients Diagnosed With Relapsing Remitting Multiple Sclerosis

Download Publication

2016

Fingolimod Versus Teiflunomide: Health Care Costs Associated With Patients Diagnosed With Relapsing Remitting Multiple Sclerosis Taking Disease Modifying Therapies in the United States

Download Publication

2016

Health Economic Evaluation of Interferon Beta 1b Versus 1a for Patients Diagnosed With Relapsing Remitting Multiple Sclerosis

Download Publication

2016

Orals Versus Subcutaneous Administration of Disease Modifying Therapies: A Comparison of Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis

Download Publication

2016

Fingolimod Versus Teiflunomide: Characteristics of Patients Diagnosed With Relapsing Remitting Multiple Sclerosis and Taking Oral Disease Modifying Therapies

Download Publication